Literature DB >> 11698348

Hepatocellular proliferation in response to a peroxisome proliferator does not require TNFalpha signaling.

S P Anderson1, C S Dunn, R C Cattley, J C Corton.   

Abstract

Rodents exposed to peroxisome proliferator xenobiotics respond with marked increases in hepatocellular replication and growth that results in tumor formation. Recently, tumor necrosis factor-alpha (TNFalpha) was proposed as the central mediator of this maladaptive response. To define the role of TNFalpha signaling in hepatocellular growth induced by peroxisome proliferators we administered three daily gavage doses of the potent peroxisome proliferator, Wy-14 643, to mice nullizygous for TNF-receptor I (TNFR1), TNFR2, or both receptors. We demonstrate here that regardless of genotype the mice responded with almost identical increases in liver to body weight ratios and hepatocyte proliferation. Lacking evidence that TNFalpha signaling mediates these effects, we then examined the possible contribution of alternative cytokine pathways. Semi-quantitative, reverse transcriptase polymerase chain reaction analysis revealed that wild type mice acutely exposed to Wy-14 643 had increased hepatic expression of Il1beta, Il1r1, Hnf4, and Stat3 genes. Moreover, hepatic adenomas from mice chronically exposed to Wy-14 643 had increased expression of Il1beta, Il1r1, Il6, and Ppargamma1. Expression of Il1alpha, Tnfalpha, Tnfr1, Tnfr2, Pparalpha, or C/ebpalpha was not altered by acute Wy-14 643 exposure or in adenomas induced by Wy-14643. These data suggest that the hepatic mitogenesis and carcinogenesis associated with peroxisome proliferator exposure is not mediated via TNFalpha but instead may involve an alternative pathway requiring IL1beta and IL6.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11698348     DOI: 10.1093/carcin/22.11.1843

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  7 in total

Review 1.  Peroxisome proliferator-activated receptors and cancer: challenges and opportunities.

Authors:  Jihan Youssef; Mostafa Badr
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

Review 2.  Modes of action and species-specific effects of di-(2-ethylhexyl)phthalate in the liver.

Authors:  Ivan Rusyn; Jeffrey M Peters; Michael L Cunningham
Journal:  Crit Rev Toxicol       Date:  2006-05       Impact factor: 5.635

Review 3.  Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand?

Authors:  Jeffrey M Peters; Connie Cheung; Frank J Gonzalez
Journal:  J Mol Med (Berl)       Date:  2005-06-23       Impact factor: 4.599

4.  Time course investigation of PPARalpha- and Kupffer cell-dependent effects of WY-14,643 in mouse liver using microarray gene expression.

Authors:  Courtney G Woods; Oksana Kosyk; Blair U Bradford; Pamela K Ross; Amanda M Burns; Michael L Cunningham; Pingping Qu; Joseph G Ibrahim; Ivan Rusyn
Journal:  Toxicol Appl Pharmacol       Date:  2007-09-16       Impact factor: 4.219

Review 5.  The PPARα-dependent rodent liver tumor response is not relevant to humans: addressing misconceptions.

Authors:  J Christopher Corton; Jeffrey M Peters; James E Klaunig
Journal:  Arch Toxicol       Date:  2017-12-02       Impact factor: 5.153

6.  Advances in understanding the regulation of apoptosis and mitosis by peroxisome-proliferator activated receptors in pre-clinical models: relevance for human health and disease.

Authors:  Eric Boitier; Jean-Charles Gautier; Ruth Roberts
Journal:  Comp Hepatol       Date:  2003-01-31

7.  Peroxisome proliferators-activated alpha agonist treatment ameliorates hepatic damage in rats with obstructive jaundice: an experimental study.

Authors:  Mehmet Cindoruk; Mustafa Kerem; Tarkan Karakan; Bulent Salman; Okan Akin; Murat Alper; Ozlem Erdem; Selahattin Unal
Journal:  BMC Gastroenterol       Date:  2007-11-28       Impact factor: 3.067

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.